Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2
BackgroundSARS-CoV2 infection in patients with comorbidities, particularly T2DM, has been a major challenge globally and has been shown to be associated with high morbidity and mortality. Here, we did whole blood immunophenotyping along with plasma cytokine, chemokine, antibody isotyping, and viral...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.848335/full |
| _version_ | 1828348617629368320 |
|---|---|
| author | Soumya Sengupta Soumya Sengupta Gargee Bhattacharya Gargee Bhattacharya Sanchari Chatterjee Sanchari Chatterjee Ankita Datey Ankita Datey Shubham K. Shaw Shubham K. Shaw Sandhya Suranjika Paritosh Nath Prakash K. Barik Punit Prasad Punit Prasad Soma Chattopadhyay Soma Chattopadhyay Rajeeb K. Swain Rajeeb K. Swain Ajay Parida Ajay Parida Satish Devadas Satish Devadas |
| author_facet | Soumya Sengupta Soumya Sengupta Gargee Bhattacharya Gargee Bhattacharya Sanchari Chatterjee Sanchari Chatterjee Ankita Datey Ankita Datey Shubham K. Shaw Shubham K. Shaw Sandhya Suranjika Paritosh Nath Prakash K. Barik Punit Prasad Punit Prasad Soma Chattopadhyay Soma Chattopadhyay Rajeeb K. Swain Rajeeb K. Swain Ajay Parida Ajay Parida Satish Devadas Satish Devadas |
| author_sort | Soumya Sengupta |
| collection | DOAJ |
| description | BackgroundSARS-CoV2 infection in patients with comorbidities, particularly T2DM, has been a major challenge globally and has been shown to be associated with high morbidity and mortality. Here, we did whole blood immunophenotyping along with plasma cytokine, chemokine, antibody isotyping, and viral load from oropharyngeal swab to understand the immune pathology in the T2DM patients infected with SARS-CoV2.MethodsBlood samples from 25 Covid-19 positive patients having T2DM, 10 Covid-19 positive patients not having T2DM, and 10 Covid-19 negative, non-diabetic healthy controls were assessed for various immune cells by analyzing for their signature surface proteins in mass cytometry. Circulating cytokines, chemokines, and antibody isotypes were determined from plasma while viral copy number was determined from oropharyngeal swabs. All our representative data corroborated with laboratory findings.ResultsOur observations encompass T2DM patients having elevated levels of both type I and type II cytokines and higher levels of circulating IgA, IgM, IgG1, and IgG2 as compared to NDM and healthy volunteers. They also displayed higher percentages of granulocytes, mDCs, plasmablasts, Th2-like cells, CD4+ EM cells, and CD8+ TE cells as compared to healthy volunteers. T2DM patients also displayed lower percentages of pDCs, lymphocytes, CD8+ TE cells, CD4+, and CD8+ EM.ConclusionOur study demonstrated that patients with T2DM displayed higher inflammatory markers and a dysregulated anti-viral and anti-inflammatory response when compared to NDM and healthy controls and the dysregulated immune response may be attributed to meta inflammation. |
| first_indexed | 2024-04-14T00:57:33Z |
| format | Article |
| id | doaj.art-a01f699b312c4e32a9869f947fd6b29a |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-14T00:57:33Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a01f699b312c4e32a9869f947fd6b29a2022-12-22T02:21:34ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-04-011310.3389/fimmu.2022.848335848335Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2Soumya Sengupta0Soumya Sengupta1Gargee Bhattacharya2Gargee Bhattacharya3Sanchari Chatterjee4Sanchari Chatterjee5Ankita Datey6Ankita Datey7Shubham K. Shaw8Shubham K. Shaw9Sandhya Suranjika10Paritosh Nath11Prakash K. Barik12Punit Prasad13Punit Prasad14Soma Chattopadhyay15Soma Chattopadhyay16Rajeeb K. Swain17Rajeeb K. Swain18Ajay Parida19Ajay Parida20Satish Devadas21Satish Devadas22Department of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaRegional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaRegional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaRegional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaSchool of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) University, Bhubaneswar, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaRegional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaRegional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaRegional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaRegional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaRegional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, IndiaDepartment of Infectious Disease Biology, Institute of Life Sciences, Bhubaneswar, IndiaRegional Centre for Biotechnology (RCB), 3rd Milestone, Faridabad-Gurgaon, IndiaBackgroundSARS-CoV2 infection in patients with comorbidities, particularly T2DM, has been a major challenge globally and has been shown to be associated with high morbidity and mortality. Here, we did whole blood immunophenotyping along with plasma cytokine, chemokine, antibody isotyping, and viral load from oropharyngeal swab to understand the immune pathology in the T2DM patients infected with SARS-CoV2.MethodsBlood samples from 25 Covid-19 positive patients having T2DM, 10 Covid-19 positive patients not having T2DM, and 10 Covid-19 negative, non-diabetic healthy controls were assessed for various immune cells by analyzing for their signature surface proteins in mass cytometry. Circulating cytokines, chemokines, and antibody isotypes were determined from plasma while viral copy number was determined from oropharyngeal swabs. All our representative data corroborated with laboratory findings.ResultsOur observations encompass T2DM patients having elevated levels of both type I and type II cytokines and higher levels of circulating IgA, IgM, IgG1, and IgG2 as compared to NDM and healthy volunteers. They also displayed higher percentages of granulocytes, mDCs, plasmablasts, Th2-like cells, CD4+ EM cells, and CD8+ TE cells as compared to healthy volunteers. T2DM patients also displayed lower percentages of pDCs, lymphocytes, CD8+ TE cells, CD4+, and CD8+ EM.ConclusionOur study demonstrated that patients with T2DM displayed higher inflammatory markers and a dysregulated anti-viral and anti-inflammatory response when compared to NDM and healthy controls and the dysregulated immune response may be attributed to meta inflammation.https://www.frontiersin.org/articles/10.3389/fimmu.2022.848335/fullSARS-CoV2type II diabeteswhole blood immunophenotypinginnate immune responseadaptive immune response |
| spellingShingle | Soumya Sengupta Soumya Sengupta Gargee Bhattacharya Gargee Bhattacharya Sanchari Chatterjee Sanchari Chatterjee Ankita Datey Ankita Datey Shubham K. Shaw Shubham K. Shaw Sandhya Suranjika Paritosh Nath Prakash K. Barik Punit Prasad Punit Prasad Soma Chattopadhyay Soma Chattopadhyay Rajeeb K. Swain Rajeeb K. Swain Ajay Parida Ajay Parida Satish Devadas Satish Devadas Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2 Frontiers in Immunology SARS-CoV2 type II diabetes whole blood immunophenotyping innate immune response adaptive immune response |
| title | Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2 |
| title_full | Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2 |
| title_fullStr | Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2 |
| title_full_unstemmed | Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2 |
| title_short | Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2 |
| title_sort | underlying co morbidity reveals unique immune signatures in type ii diabetes patients infected with sars cov2 |
| topic | SARS-CoV2 type II diabetes whole blood immunophenotyping innate immune response adaptive immune response |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.848335/full |
| work_keys_str_mv | AT soumyasengupta underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT soumyasengupta underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT gargeebhattacharya underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT gargeebhattacharya underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT sancharichatterjee underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT sancharichatterjee underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT ankitadatey underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT ankitadatey underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT shubhamkshaw underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT shubhamkshaw underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT sandhyasuranjika underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT paritoshnath underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT prakashkbarik underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT punitprasad underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT punitprasad underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT somachattopadhyay underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT somachattopadhyay underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT rajeebkswain underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT rajeebkswain underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT ajayparida underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT ajayparida underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT satishdevadas underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 AT satishdevadas underlyingcomorbidityrevealsuniqueimmunesignaturesintypeiidiabetespatientsinfectedwithsarscov2 |